Keyt Bruce's Form 4 filing
IGM Biosciences, Inc. (IGMS) · filed Jun 18, 2024
- Accession no.
- 0001415889-24-017497
- Filed
- Jun 18, 2024
- Trade date
- May 15-Jun 14, 2024
- Filing delay
- 34 daysLate
- Rule 10b5-1 plan
- Not checked
This filing lists 2 non-derivative transactions. Open-market sales total $8.38K. It was filed 34 days after the trade, past the 2-business-day deadline.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Keyt BruceCIK 0001787362 | Officer (CHIEF SCIENTIFIC OFFICER) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| May 15, 2024 | Common Stock | AGrant or awardAcquired | +3,000 | $5.02 | +$15,060 | 198,875 | Direct | |
| Jun 14, 2024 | Common Stock | SSaleDisposed | −1,106 | $7.58F3 | −$8,383.48 | 197,769 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F3
This transaction was executed in multiple trades at prices ranging from $7.26 to $7.94. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
Referenced by the price of 1 transaction in Table I.